Clinical Data Update: DeltEx DRI Auto, DeltEx Allo, DeltEx nsCAR-T INB-300 & iPSC Derived Gamma-Delta T Cells
Time: 9:45 am
day: Conference Day One
Details:
- DeltEx DRI Auto, is a genetically modified autologous gamma-delta T cell product candidate for the treatment of newly diagnosed GBM solid tumors
- DeltEx Allo, is an allogeneic product candidate initially developed for the treatment of patients with acute leukemia
- DeltEx nsCAR-T INB-300 is our DeltEx DRI non-signaling CAR (nsCAR) platform with several preclinical product candidates, including the INB-330 program targeting CD-33 for AML
